What is LL-37, and what do the studies show?
Reviewed 27 sourcesPublished by PepVault
LL-37 is the body's only cathelicidin, an antimicrobial peptide. What it does, what its leg and foot ulcer trials found, and what injected use rests on.

- Last reviewed
- Sources
- 27
- Questions
- 8
- Compounds
- 4
The short answer
LL-37 is the human body's only cathelicidin: a 37-amino-acid antimicrobial peptide cut from a larger protein, hCAP-18, mainly by white blood cells and skin. It kills microbes, signals immune cells and helps wounds close. As a drug it has been tested mostly on wounds: a small leg ulcer trial looked promising, but the larger trial missed its goal. Injected under the skin, it has never been studied in people.
- LL-37 is cut from the 170-amino-acid protein hCAP-18; people with morbus Kostmann, who lack it, have severe gum disease.
- On venous leg ulcers, the 148-person HEAL LL-37 trial closed 26.5% of wounds against 25.3% on placebo; only a large-wound subgroup looked better.
- Too much LL-37 is part of the story of psoriasis and rosacea, so more is not simply better.
- Injected LL-37 has no human study except a four-person trial that put it into melanoma tumors.
Evidence: Small human trials of LL-37 on wounds (34, 148 and 25 people) and one open-label oral COVID-19 trial; injected LL-37 has only a four-person tumor-injection trial; the rest is cell, animal and observational work.

What is LL-37?
LL-37 is a chain of 37 amino acids, the building blocks of proteins, named for its first two, both leucine (L), and its length1. Your cells first make it as part of a larger protein called hCAP-18, 170 amino acids long, and LL-37 is its tail end, positions 134 to 1701. Neutrophils, the most common white blood cells, store hCAP-18 and release it, and an enzyme called proteinase 3 snips LL-37 free outside the cell4.
Cathelicidins are a family of antimicrobial proteins stored in neutrophils across mammals4. Humans make one: the gene for hCAP-18 is the only cathelicidin gene in the human genome3. Swedish researchers found it in 1995 in a bone marrow library and first called it FALL-392; a year later they showed the form cells actually release is two amino acids shorter, LL-373. It is made in skin, the gut, the airways, the testis and many kinds of white blood cell5. It weighs about 4,493 g/mol, carries a net positive charge (+6, counted from its sequence) and binds lipopolysaccharide, the negatively charged outer coat of many bacteria1.
The Peptide Sky draws LL-37 bead by bead, in its measured X-ray shape.
Peptide SkySee LL-37 as a molecule53 peptides as a night sky in 3D. Each star opens into its molecule, one bead per amino acid, with the measured shape where one exists.Open the Peptide Sky
What does LL-37 do in the body?
- It attacks microbes. In a dish, synthetic LL-37 was "a potent antibacterial peptide"3, it acts on a broad range of microbes5, and it punches pores in their membranes1. Against Pseudomonas, a hard-to-treat germ, it was a weak killer (it took 64 µg/mL) but stopped biofilms, the slimy colonies bacteria shelter in, at 0.5 µg/mL6.
- It signals the immune system. It binds and neutralizes endotoxin, the bacterial fragment that sets off inflammation, and calls immune cells to a wound or infection5.
- It helps wounds close. In people, hCAP-18 in skin rises after a cut and peaks at 48 hours; in human skin kept alive in the lab, blocking LL-37 with antibodies slowed new skin growing over the wound. The edge of chronic ulcers showed no LL-37 at all7. It also grows new blood vessels in rabbit and mouse models8.
The clearest sign that it matters in people comes from morbus Kostmann, an inborn shortage of neutrophils. Treatment restores the neutrophil count, yet infections continue. In a 2002 study of six patients, none had detectable LL-37 precursor in plasma or saliva, and all had severe gum disease, except one who had received a bone-marrow transplant: near-normal LL-37, normal teeth9.
Species note: the microbe-killing and biofilm results are in a dish, the blood-vessel results in rabbits and mice, and the wound result in human skin in the lab. The Kostmann finding is an observation in six people, not a treatment test.
Has LL-37 been tested as a treatment in people?
Yes, five times, as of November 2026, and mostly as a solution or cream put on a wound. The ulcer trials gave LL-37 twice a week, at dressing changes.
| Trial | People | How LL-37 was given | What it found |
|---|---|---|---|
| Venous leg ulcers, phase 1/2, Sweden, 201410 | 34 | On the wound, 0.5, 1.6 or 3.2 mg/mL, for 4 weeks | Healing rate about six times placebo's at 0.5 mg/mL (p = 0.003); 3.2 mg/mL no better than placebo |
| HEAL LL-37, venous leg ulcers, phase 2b, Poland and Sweden, 202111 | 148 | On the wound, 0.5 or 1.6 mg/mL, for 13 weeks | Missed its goal: 26.5% and 24.7% of ulcers closed, against 25.3% on placebo |
| Diabetic foot ulcers, Jakarta, 202312 | 25 | Cream on the wound for 4 weeks | More new healing tissue at every check (p = 0.006 to 0.037); bacteria and inflammation markers no lower than placebo |
| COVID-19 (Omicron), inpatients, China, 202313 | 238 | By mouth, as engineered bacteria that make LL-37 | Started by day 6 after diagnosis, mean time to a negative virus test 9.80 against 14.04 on placebo; open-label |
| Melanoma, MD Anderson, phase 1/214 | 4 | Injected into skin tumors, weekly for up to 8 weeks | Results posted for 3; no published paper |
The first leg ulcer trial is the one quoted most: its two lower strengths cut mean ulcer area by 68% and 50% in four weeks10. Its top strength did nothing, a pattern that returned.
In the foot ulcer trial, 13 people used LL-37 cream and 12 a placebo cream. The measure that improved was the granulation index, the share of the wound's area covered by fresh healing tissue, not full closure. One person on LL-37 had mild skin irritation from wound fluid12. Our study page has the full numbers: pepvault.app/research/ll-37-miranda-2023.
Why did the larger leg ulcer trial fail?
HEAL LL-37 was built to confirm the 2014 result, with more than four times the patients, for 13 weeks, on top of compression bandaging. Its main goal was complete wound closure confirmed two weeks later, and LL-37 matched placebo11. Ulcers on placebo also shrank more on average: 51.7%, against 35.6% at 0.5 mg/mL and 4.0% at 1.6 mg/mL, none of these gaps significant11.
One group looked different. In wounds of 10 cm² or more at the start, 28.1% closed on the lower strength against 8.1% on placebo11. That was a post hoc analysis (pepvault.app/glossary/post-hoc-analysis), one chosen after the results were in, so it is a lead for the next trial, not a finding. The sponsor, Promore Pharma, develops LL-37 under the drug name ropocamptide11.
In both trials the lower strength did best1011: on a wound, more LL-37 was not better.
Can too much LL-37 cause problems?
Yes. The stickiness that lets LL-37 grab bacteria also lets it grab the body's own DNA.
- Psoriasis. LL-37 binds fragments of the body's own DNA into clumps that a type of immune cell, the plasmacytoid dendritic cell, mistakes for a virus, setting off interferon, a strong inflammatory signal; this was shown in human immune cells and psoriasis skin samples16. Later, two-thirds of people with moderate to severe plaque psoriasis were found to carry T cells aimed at LL-37 itself, and their presence tracked disease activity17.
- Rosacea. People with rosacea have abnormally high cathelicidin in their facial skin, cut into unusual pieces by an overactive skin enzyme. In mice, injecting those pieces inflamed the skin, and mice lacking the cathelicidin gene confirmed its part in the inflammation18.
- Lupus and more. A review ties LL-37 to lupus, rheumatoid arthritis and atherosclerosis19.
So LL-37 is a dial, not a switch: too little and wounds and gums suffer79, too much and the skin can turn on itself1618.
How is vitamin D linked to LL-37?
Directly. The gene for hCAP-18 carries a landing spot for the vitamin D receptor, and active vitamin D switches the gene on strongly in human immune and skin cells20. That landing spot is found in primates and is missing in mice, rats and dogs, so mouse studies of vitamin D and immunity miss this link20. In human macrophages, the immune cells that swallow germs, a danger signal raised the vitamin D machinery, made cathelicidin and killed tuberculosis bacteria inside the cells; serum low in vitamin D supported the response poorly21.
Whether taking vitamin D raises LL-37 depends on where you look:
| Study | Who | Vitamin D given | LL-37 result |
|---|---|---|---|
| Hata 200822 | 14 with eczema, 14 without | 4,000 IU a day for 21 days, no placebo group | In eczema patches, cathelicidin gene activity rose from a median 3.53 to 23.91 units; normal skin, no significant change |
| Das 201423 | 131 young women low in vitamin D | 60,000 IU weekly for 8 weeks, then every 2 weeks, to 6 months, against placebo | No change in LL-37 gene activity in blood cells |
| Quraishi 201524 | 30 ICU patients with sepsis | One dose of 200,000 or 400,000 IU, against placebo | Blood LL-37 up 30% on the higher dose by day 5, down 17% on placebo |
These are study doses, not advice. The link is real at the gene, but in healthy people low in vitamin D, six months of it did not move LL-37 gene activity in blood cells23. pepvault.app/peptides/vitamin-d3-k2 covers the supplement.
What do injected-LL-37 reports rest on?
On the lab work above and on users' own reports. No trial has given LL-37 under the skin, the way it is used outside trials. The only injected human data come from the melanoma trial, which put 250 or 500 µg into each skin tumor once a week14. A case report from the same cancer center describes a 63-year-old woman who had eight weekly injections into her tumors; the injected tumors shrank, but about 45 days in she developed raised, wart-like skin lesions across her body, which cleared within two months of stopping15.
The FDA's summary, current as of April 22, 2026, says it "lacks sufficient safety-related information" on LL-37, flags a risk of immunogenicity, the immune system reacting against the peptide, and notes that nonclinical research suggests "detrimental effects on male reproduction" and that the drug can promote tumor growth in some tissues25. A 2023 lab study points the same way: LL-37 raised invasion-linked signals in human melanoma cells, and its mouse version did so in mouse melanomas27.
Commonly reported: redness or itching where it was injected, and for some a mild flu-like, achy feeling in the first few days that passes.
In PepVault you can log a symptom such as injection-site redness with a 1-to-5 rating against the compound it belongs to, and read the entries back by date. Log it in PepVault
When to get help Redness that keeps spreading, a fever, or new raised spots on the skin are reasons to see a clinician.
Is LL-37 approved or legal to prescribe?
As of November 2026, no LL-37 product is approved by the FDA. The FDA lists cathelicidin LL-37 among bulk drug substances "nominated but withdrawn", which means US pharmacies have no route to compound it today25. The FDA's compounding advisory committee is due to discuss LL-37, with GHK-Cu, melanotan II, dihexa and PEG-MGF, at a meeting "before the end of February 2027" (FDA page current as of April 15, 2026)26. pepvault.app/peptides/ll-37/legal-status has the FDA, DEA and sport rules; our FDA peptide panel guide explains the meeting.
If your clinician sets you a plan, PepVault keeps each compound on its own line with its own time and an optional reminder, and logs every dose as you took it. Set reminders in PepVault
Sources
- UniProt P49913, CAMP_HUMAN: cathelicidin antimicrobial peptide (hCAP-18; LL-37 = residues 134-170). rest.uniprot.org
- Agerberth B et al. FALL-39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis. Proc Natl Acad Sci U S A. 1995. PubMed 7529412
- Gudmundsson GH et al. The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. Eur J Biochem. 1996. PubMed 8681941
- Sørensen OE et al. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood. 2001. PubMed 11389039
- Dürr UH et al. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta. 2006. PubMed 16716248
- Overhage J et al. Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect Immun. 2008. PubMed 18591225
- Heilborn JD et al. The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J Invest Dermatol. 2003. PubMed 12603850
- Koczulla R et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest. 2003. PubMed 12782669
- Pütsep K et al. Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. Lancet. 2002. PubMed 12387964
- Grönberg A et al. Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial. Wound Repair Regen. 2014. PubMed 25041740
- Mahlapuu M et al. Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: a multicentric prospective randomized placebo-controlled clinical trial (HEAL LL-37). Wound Repair Regen. 2021. PubMed 34687253
- Miranda E et al. Efficacy of LL-37 cream in enhancing healing of diabetic foot ulcer: a randomized double-blind controlled trial. Arch Dermatol Res. 2023. PubMed 37480520
- Zhao Y et al. Efficacy and safety of Oral LL-37 against the Omicron BA.5.1.3 variant of SARS-CoV-2: a randomized trial. J Med Virol. 2023. PubMed 37605995
- ClinicalTrials.gov NCT02225366. Intratumoral injections of LL37 for melanoma (M.D. Anderson Cancer Center), results posted December 9, 2021. clinicaltrials.gov
- Dolkar T et al. Dermatologic toxicity from novel therapy using antimicrobial peptide LL-37 in melanoma: a detailed examination of the clinicopathologic features. J Cutan Pathol. 2018. PubMed 29665030
- Lande R et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007. PubMed 17873860
- Lande R et al. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun. 2014. PubMed 25470744
- Yamasaki K et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007. PubMed 17676051
- Kahlenberg JM, Kaplan MJ. Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease. J Immunol. 2013. PubMed 24185823
- Gombart AF et al. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J. 2005. PubMed 15985530
- Liu PT et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006. PubMed 16497887
- Hata TR et al. Administration of oral vitamin D induces cathelicidin production in atopic individuals. J Allergy Clin Immunol. 2008. PubMed 19014773
- Das M et al. Effect of vitamin D supplementation on cathelicidin, IFN-γ, IL-4 and Th1/Th2 transcription factors in young healthy females. Eur J Clin Nutr. 2014. PubMed 24398649
- Quraishi SA et al. Effect of cholecalciferol supplementation on vitamin D status and cathelicidin levels in sepsis: a randomized, placebo-controlled trial. Crit Care Med. 2015. PubMed 26086941
- FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). fda.gov
- FDA. Meeting of the Pharmacy Compounding Advisory Committee (content current as of April 15, 2026). fda.gov
- Ohuchi K et al. LL-37 might promote local invasion of melanoma by activating melanoma cells and tumor-associated macrophages. Cancers (Basel). 2023. PubMed 36980564
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.